Pyxis Oncology (PYXS) Competitors $1.16 -0.03 (-2.52%) Closing price 04:00 PM EasternExtended Trading$1.17 +0.01 (+0.78%) As of 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PYXS vs. SGMT, DBVT, ANNX, AVTE, ALLO, TVRD, ZYBT, CRDF, MREO, and KODShould you be buying Pyxis Oncology stock or one of its competitors? The main competitors of Pyxis Oncology include Sagimet Biosciences (SGMT), DBV Technologies (DBVT), Annexon (ANNX), Aerovate Therapeutics (AVTE), Allogene Therapeutics (ALLO), Tvardi Therapeutics (TVRD), Zhengye Biotechnology (ZYBT), Cardiff Oncology (CRDF), Mereo BioPharma Group (MREO), and Kodiak Sciences (KOD). These companies are all part of the "pharmaceutical products" industry. Pyxis Oncology vs. Its Competitors Sagimet Biosciences DBV Technologies Annexon Aerovate Therapeutics Allogene Therapeutics Tvardi Therapeutics Zhengye Biotechnology Cardiff Oncology Mereo BioPharma Group Kodiak Sciences Sagimet Biosciences (NASDAQ:SGMT) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation. Is SGMT or PYXS more profitable? Sagimet Biosciences' return on equity of -35.21% beat Pyxis Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Sagimet BiosciencesN/A -35.21% -34.09% Pyxis Oncology N/A -57.49%-45.17% Do analysts prefer SGMT or PYXS? Sagimet Biosciences currently has a consensus price target of $26.60, indicating a potential upside of 180.30%. Pyxis Oncology has a consensus price target of $9.00, indicating a potential upside of 675.86%. Given Pyxis Oncology's higher probable upside, analysts clearly believe Pyxis Oncology is more favorable than Sagimet Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sagimet Biosciences 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Pyxis Oncology 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media prefer SGMT or PYXS? In the previous week, Pyxis Oncology had 1 more articles in the media than Sagimet Biosciences. MarketBeat recorded 2 mentions for Pyxis Oncology and 1 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 1.89 beat Pyxis Oncology's score of 0.99 indicating that Sagimet Biosciences is being referred to more favorably in the media. Company Overall Sentiment Sagimet Biosciences Very Positive Pyxis Oncology Positive Which has more volatility & risk, SGMT or PYXS? Sagimet Biosciences has a beta of 3.35, meaning that its stock price is 235% more volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Which has stronger valuation & earnings, SGMT or PYXS? Sagimet Biosciences has higher revenue and earnings than Pyxis Oncology. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSagimet Biosciences$2M145.53-$45.57M-$1.76-5.39Pyxis OncologyN/AN/A-$77.33M-$1.59-0.73 Do insiders and institutionals have more ownership in SGMT or PYXS? 87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 14.7% of Sagimet Biosciences shares are owned by company insiders. Comparatively, 10.6% of Pyxis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummarySagimet Biosciences beats Pyxis Oncology on 10 of the 14 factors compared between the two stocks. Get Pyxis Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PYXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PYXS vs. The Competition Export to ExcelMetricPyxis OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$71.86M$2.69B$5.53B$9.30BDividend YieldN/A1.70%4.59%4.02%P/E Ratio-0.738.9428.5619.60Price / SalesN/A427.73360.9274.26Price / CashN/A22.3424.7327.56Price / Book0.574.608.155.56Net Income-$77.33M$30.99M$3.24B$257.73M7 Day Performance2.65%0.78%2.01%0.97%1 Month Performance-3.33%23.12%8.27%10.70%1 Year Performance-63.75%-5.47%28.39%15.67% Pyxis Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PYXSPyxis Oncology2.1275 of 5 stars$1.16-2.5%$9.00+675.9%-62.2%$71.86MN/A-0.7360SGMTSagimet Biosciences2.6415 of 5 stars$9.46-0.1%$26.60+181.2%+184.1%$290.14M$2M-5.388Positive NewsDBVTDBV Technologies3.9844 of 5 stars$10.58-2.1%$14.75+39.5%+164.4%$289.68M$4.15M-2.1580Positive NewsGap UpANNXAnnexon2.5098 of 5 stars$2.61+1.2%$12.50+378.9%-57.1%$286.34MN/A-2.2160AVTEAerovate TherapeuticsN/A$9.82-6.7%N/A-84.5%$284.63MN/A-3.2820High Trading VolumeALLOAllogene Therapeutics3.5419 of 5 stars$1.29+0.8%$8.44+554.6%-53.3%$282.16M$20K-1.05310News CoveragePositive NewsTVRDTvardi TherapeuticsN/A$29.83+9.1%$64.25+115.4%N/A$279.21M$7.14M0.0080News CoverageAnalyst ForecastAnalyst RevisionHigh Trading VolumeZYBTZhengye BiotechnologyN/A$5.87-0.3%N/AN/A$276.86M$186.36M0.00278CRDFCardiff Oncology1.2474 of 5 stars$4.13+1.5%$11.70+183.3%+64.5%$274.77M$680K-4.4920MREOMereo BioPharma Group1.5778 of 5 stars$1.72+6.8%$7.20+318.6%-58.6%$273.48M$10M-24.5740High Trading VolumeKODKodiak Sciences4.0566 of 5 stars$5.17+14.1%$9.00+74.1%+72.3%$272.77MN/A-1.4290Gap Up Related Companies and Tools Related Companies SGMT Alternatives DBVT Alternatives ANNX Alternatives AVTE Alternatives ALLO Alternatives TVRD Alternatives ZYBT Alternatives CRDF Alternatives MREO Alternatives KOD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PYXS) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pyxis Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pyxis Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
